Guardant Begin Period Cash Flow from 2010 to 2025

GH Stock  USD 45.84  0.62  1.33%   
Guardant Health's Begin Period Cash Flow is increasing with slightly volatile movements from year to year. Begin Period Cash Flow is estimated to finish at about 1.2 B this year. Begin Period Cash Flow is the amount of cash Guardant Health has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2017-09-30
Previous Quarter
B
Current Value
688.4 M
Quarterly Volatility
359.4 M
 
Covid
Check Guardant Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Guardant Health's main balance sheet or income statement drivers, such as Tax Provision of 1.3 M, Net Interest Income of 53.7 M or Interest Income of 56.4 M, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0022 or Days Sales Outstanding of 88.45. Guardant financial statements analysis is a perfect complement when working with Guardant Health Valuation or Volatility modules.
  
Check out the analysis of Guardant Health Correlation against competitors.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.

Latest Guardant Health's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Guardant Health over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Guardant Health's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Guardant Health's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Guardant Begin Period Cash Flow Regression Statistics

Arithmetic Mean263,190,209
Geometric Mean42,116,804
Coefficient Of Variation158.10
Mean Deviation324,570,314
Median72,596,000
Standard Deviation416,098,110
Sample Variance173137.6T
Range1.2B
R-Value0.76
Mean Square Error77608.6T
R-Squared0.58
Significance0.0006
Slope66,654,147
Total Sum of Squares2597064.6T

Guardant Begin Period Cash Flow History

20251.2 B
20241.1 B
2023141.9 M
2022492.3 M
2021833 M
2020143.2 M
2019140.5 M

About Guardant Health Financial Statements

Investors use fundamental indicators, such as Guardant Health's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Guardant Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Begin Period Cash Flow1.1 B1.2 B

Currently Active Assets on Macroaxis

Check out the analysis of Guardant Health Correlation against competitors.
For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.56)
Revenue Per Share
6.021
Quarterly Revenue Growth
0.302
Return On Assets
(0.17)
Return On Equity
(45.84)
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.